The most revealing detail in Slim Now TN’s advertised care pathway is not a price. It is the statement that the first administration takes place in the office, alongside a separate offer of telehealth visits throughout Tennessee. Those two services could fit together, but the consulted pages do not explain how. For someone seeking care remotely, that missing connection matters: an online consultation is not necessarily a fully remote treatment pathway, and medication intended for home administration is not necessarily medication shipped to the home.
This review follows the responsibilities a prospective patient would need to understand: who conducts the consultation, what the advertised payment includes, who supplies the medicine and how follow-up works. Public documentation consulted October 19, 2026 identifies a local practice, named clinicians and presentation-specific monthly prices. It does not identify the dispensing pharmacy or establish the exact products supplied. The result is a relatively visible front end of care, followed by a less documented transition into dispensing, home use and ongoing service.
At a glance
- Location and reach
- Slim Now TN lists 5607 Franklin Rd, Murfreesboro, TN 37128, and advertises telehealth visits in Tennessee; the consulted pages do not establish access in other states.Sources: [3]
- Consultation access
- Appointments can be requested through the office, a website form or info@slimnowtn.com. The published office phone is 615-439-6929.Sources: [3]
- Conflicting initial prices
- A general offer advertises a $195 first month, while the semaglutide table lists 0.25 mg at $85 per month with an initial consultation. Their relationship is not explained.Sources: [3]
- First administration
- Initial GLP-1 options describe medication-use instructions and a first administration in the office. The telehealth alternative to that step is not documented.Sources: [3]
- Ongoing care
- Subsequent pricing entries describe monthly provider checkups, progress and vital-sign measurements, and medication for home administration; they do not establish home shipping.Sources: [3]
Start by establishing whether the pathway is local or remote
Slim Now TN advertises semaglutide and tirzepatide and lists a Murfreesboro location at 5607 Franklin Rd, Tennessee 37128. Its published hours are Monday through Thursday, 8 a.m. to 5 p.m.; Friday, 8 a.m. to noon; and every other Saturday, 9 a.m. to 2 p.m. These details give prospective patients a concrete office to contact rather than only an online enrollment page. The alternating Saturday schedule still requires confirmation for a particular appointment, and office hours do not establish an after-hours clinical service.
The practice also explicitly offers telehealth visits in Tennessee. That is a stated geographic service boundary, not evidence of nationwide availability. Before arranging care, a remote patient should establish which steps can occur by telehealth and whether any office visit remains necessary. Our guide to the care journey from intake through follow-up helps distinguish those stages. Here, the important unanswered point is how Tennessee telehealth connects with the practice’s advertised first administration in the office—not whether the website offers a remote appointment at all.
Booking establishes contact, not a complete clinical intake
The documented entry point is to contact the office for a consultation with a provider. Slim Now TN publishes 615-439-6929 and info@slimnowtn.com, and it also invites appointment requests through a form. These are useful, direct contact paths, but the pages do not promise a response time, a consultation date or a prescribing decision. Sending a message should therefore be understood as requesting access to an evaluation, not completing enrollment or securing a prescription. No separate clinical portal is established by the documentation reviewed.
The next step needs more explanation from the practice. The consulted pages do not spell out GLP-1 minimum age, BMI criteria, required laboratory work, exclusion criteria or the complete medical-history review. They also do not establish whether testing has a separate charge. A productive booking conversation would ask what records to bring, whether laboratory results are needed before the visit, how a remote assessment is conducted and what happens if treatment is not offered. These are unresolved service questions, not grounds for assuming either automatic eligibility or inadequate evaluation.
Named clinicians provide a starting point for assigning responsibility
Slim Now TN identifies Madison Umbeck as FNP-C, MSCP and describes her as a board-certified family nurse practitioner. It attributes her nursing bachelor’s degree to Saint Louis University and her nursing master’s degree to Belmont University. The site identifies owner J. Seth Weathersby as PA-C, with a bachelor’s degree in exercise science and a Master of Medicine from Trevecca Nazarene University. These are provider-published biographies, not independently verified licensing findings. A nurse practitioner or physician assistant should not be relabeled as a physician when describing this team.
The practice also says Weathersby serves on Tennessee’s state board for physician assistants and has more than 20 years of urgent-care experience. Shelby Turvey is listed as FNP-C with more than 30 years in healthcare. Naming staff makes it possible to ask who will actually perform the initial evaluation, authorize medication and review subsequent concerns. It does not establish that a particular team member will handle every visit. The consulted pages also leave the operating legal entity and arrangements for coverage during a clinician’s absence unclear.
The first payment needs a written explanation before treatment begins
Slim Now TN’s general offer says the first month of the program costs $195, followed by its published payment schedule. However, its semaglutide table lists the 0.25 mg presentation at $85 per month, including an initial provider consultation. The tirzepatide table lists 2.5 mg at $195 per month, also including the initial consultation. The pages do not reconcile the general offer with the lower semaglutide entry. Neither amount should be treated as a universal first bill without confirmation of the selected option and what the practice will actually collect.
Subsequent advertised semaglutide entries are $125 per month for 0.50 mg, $200 for 1 mg, $250 for 1.50 mg and $300 for 2 mg. Tirzepatide entries are $295 per month for 5 mg, $395 for 7.5 mg and $495 for 10 mg. These are the site’s presentation labels and prices, not instructions to select or change a dose. The practice explicitly warns that price increases with an increase in dosage. The following table summarizes the commercial structure without assuming a treatment sequence.
| Published option | Advertised charge | Included service or unresolved condition |
|---|---|---|
| General first-month offer | $195 for the first month | Not reconciled with the $85 initial semaglutide listing |
| Semaglutide, 0.25 mg | $85 per month | Initial provider consultation; initial-option instructions describe office administration |
| Semaglutide, 0.50 / 1 / 1.50 / 2 mg | $125 / $200 / $250 / $300 per month, respectively | Monthly provider checkup, progress and vital-sign measurements |
| Tirzepatide, 2.5 mg | $195 per month | Initial provider consultation; initial-option instructions describe office administration |
| Tirzepatide, 5 / 7.5 / 10 mg | $295 / $395 / $495 per month, respectively | Monthly provider checkup, progress and vital-sign measurements |
Instruction and the first administration are documented; the remote alternative is not
The initial GLP-1 options describe instructions on using the medication and a first administration in the office. The site’s general description discusses injections under the skin, while the pricing information describes medication for administration at home. Together, these statements outline an office-to-home model: consultation and instruction first, then home use. They do not establish the exact commercial formulation, device, package contents or quantity supplied. A monthly program price also does not by itself define a calendar dispensing date or the number of administrations provided.
For telehealth patients, the practice needs to explain whether the office step still applies, whether another teaching arrangement is available and who checks that the patient understands the supplied product. That question should be answered before payment or travel plans, rather than inferred from the availability of video visits. The product, route and pharmacy checklist is useful here because an ingredient name is not a complete product description. The review cannot supply missing instructions or turn presentation labels into a patient dosing plan.
The pharmacy handoff is the least visible part of the service
The consulted documentation does not identify the dispensing pharmacy, manufacturer, brand or exact formulation supplied. A reference to a pharmacy partner is not enough to resolve those questions without the partner’s identity and role. The pages also do not establish whether medication is collected at the office or shipped, who arranges that transfer, what shipping costs, or when it should arrive. Home administration describes where medication is used; it does not prove home delivery. The practical pharmacy handoff questions begin with identifying who will dispense and label the prescription.
These gaps also prevent a product-specific regulatory conclusion. FDA approval applies to a particular product, not to a clinic or an ingredient name alone. Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality; nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. The available information does not establish that Slim Now TN supplies compounded medication, approved branded medication or a particular alternative formulation.
If shipping is part of the eventual arrangement, responsibility for a delayed or temperature-compromised package should be clarified in advance. The practice’s public documentation does not set out a carrier, refrigeration procedure, arrival window or replacement policy. FDA specifically advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. That is general regulatory guidance, not evidence of a delivery problem at Slim Now TN. It nevertheless makes identifying the dispensing pharmacy operationally important, not merely an administrative preference.
Monthly checkups are more specific than the support arrangements
For the subsequent semaglutide and tirzepatide entries, Slim Now TN advertises monthly provider checkups and measurement of progress and vital signs. That is a meaningful description of scheduled follow-up rather than merely a recurring medication charge. However, the pages do not explain how vital signs are obtained during telehealth, how appointments are scheduled or who handles concerns between visits. Readers should distinguish that documented monthly encounter from an assumed promise of unlimited messaging, rapid replies or continuous clinical availability, none of which is established here.
A useful follow-up discussion would establish the contact route for a medication problem, expected response time and arrangements outside posted office hours. NIDDK describes medication selection and follow-up as involving benefits, adverse effects, health conditions, other medicines and treatment response—not just the next payment. Our guide to what ongoing GLP-1 support means separates scheduled reviews from between-visit access. Slim Now TN’s published monthly checkup is a starting point for that conversation, but the documentation does not show how the practice manages every concern that might arise before the next appointment.
Administrative boundaries need the same attention as the clinical handoff
The monthly prices do not resolve billing mechanics. The consulted pages do not publish minimum commitments, automatic-renewal rules, cancellation deadlines, refunds, prepayment terms or discounts. They also do not specify insurance acceptance, reimbursement, taxes, additional charges or laboratory coverage. A prospective patient should request the applicable terms rather than assume that a monthly price means either a cancellable subscription or a fixed commitment. A cancellation right, if later provided, would not by itself establish a refund right. The first invoice and the ongoing agreement need separate clarification.
The public privacy policy discusses website comments: it says comment submissions collect form information, IP addresses and browser identifiers, and that comments and metadata are retained indefinitely. It permits requests to erase personal data, subject to administrative, legal and security retention exceptions. Those statements do not establish clinical-record retention periods or explain the telehealth handling of medical information. The consulted documentation also lacks the content of the HIPAA link. Before sending sensitive history through a general contact route, patients can ask which channel the practice designates for clinical intake and records.
Questions & answers
Can I complete Slim Now TN treatment entirely through telehealth?
That is not established. Slim Now TN advertises Tennessee telehealth, but its initial GLP-1 options also describe a first administration in the office. Ask whether an in-person visit is required, whether remote instruction is available and how medication reaches you afterward. The public pages do not establish availability outside Tennessee or a fully remote pathway within it.
Is the first month $85 or $195?
Both amounts appear in different places. The general program offer says $195 for the first month. The semaglutide 0.25 mg listing says $85 per month with an initial consultation; tirzepatide 2.5 mg is listed at $195 per month with that consultation. Ask for a written, option-specific first-payment breakdown because the pages do not explain how the general offer and semaglutide listing fit together.
Does Slim Now TN name the pharmacy or confirm an FDA-approved product?
The consulted pages do neither. They advertise ingredient names but do not establish the dispensing pharmacy, brand, manufacturer or exact formulation. Ask for those details before treating a quote as a complete description of the medicine. FDA approval is product-specific; the presence of semaglutide or tirzepatide in the advertising does not establish the regulatory status of what would actually be dispensed.
What follow-up is advertised with later monthly prices?
The later semaglutide and tirzepatide pricing entries describe a monthly provider checkup and measurement of progress and vital signs. The pages do not establish unlimited messaging, response targets or after-hours coverage. Remote patients should also ask how vital signs are obtained. Those details distinguish the advertised scheduled encounter from whatever support may be available between appointments.
Does the NAD+ offering change the documented GLP-1 eligibility rules?
No such connection is documented. Slim Now TN separately advertises NAD+ at $50 per month for a presentation labeled 50 mg. Its NAD+ section lists pregnancy or breastfeeding, active cancer, severe liver or kidney failure and known NAD+ allergies as situations in which it says not to take that product. Those statements should not be repurposed as the practice’s GLP-1 eligibility criteria or interpreted as a requirement to purchase NAD+.
How do I ask about cancellation and transferring care?
Use the published office phone, email or appointment contact route to request the applicable agreement. Ask when future charges stop, whether any payment is refundable, how unused medication is handled and how records can be transferred. The consulted pages do not publish cancellation, renewal or refund terms. Their general personal-data erasure language also does not establish that clinical records can be deleted on request.
Our assessment
Slim Now TN documents a recognizable local care model: a Murfreesboro office, named clinicians, Tennessee telehealth, initial instruction and monthly provider checkups tied to published medication prices. Those are useful points of access and accountability. The weaker part of the public record is the transition from consultation to the actual product and its delivery, especially for remote patients. Before paying, the most useful next step is a written explanation of the first charge, any required office visit, the exact medicine and dispensing pharmacy, and ongoing support and cancellation terms. The documentation supports investigating the service further, but not assuming a fully specified end-to-end pathway.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.